Aligos Therapeutics to Present at the Cantor Global Healthcare Conference
The fireside chat premieres online Wednesday, Sept. 9, 2026 at 8:00 a.m. ET, with a webcast replay available for at least 30 days after.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Aligos Therapeutics (ALGS) will present at the Cantor Global Healthcare Conference during a fireside chat scheduled for Wednesday, September 9, 2026, at 8:00 a.m. ET.
The presentation will premiere online at that time and can be accessed via the Presentation & Events section of the Investors page on Aligos’ website. A webcast replay will be available for at least 30 days following the event.
Details
News Market Reaction – ALGS
On Sep 2, the day this news came out, ALGS closed 1.97% above the previous close. Argus tracked a peak move of +4.6% during that session. Our momentum scanner recorded 5 alerts for this stock that day. Relative volume reached 5.8x the daily average during tracking.
Data tracked by StockTitan Argus for the Sep 2 session.
Key Figures
- Conference date
- September 9, 2026
- Cantor Global Healthcare Conference
- Presentation time
- 8:00am ET
- Cantor Global Healthcare Conference fireside chat
- Replay availability
- at least 30 days
- Webcast replay following the presentation
Historical Context
-
Partner dosed the first participant in an ALG-170675 Phase 1 study.
-
Licensing revenue and narrowed net loss accompanied hepatitis B pipeline progress.
-
The company scheduled release of second-quarter 2026 financial results.
-
The B-SUPREME study completed enrollment across HBeAg-positive and HBeAg-negative cohorts.
-
Aligos received a $25M upfront payment from its Greater China license deal.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will present at the Cantor Global Healthcare Conference.
Cantor Global Healthcare Conference
- Fireside Chat on Wednesday, September 9, 2026 at 8:00am ET
The presentation will premiere at the time listed above and can be accessed by visiting the Presentation & Events section on the “Investors” page of Aligos’ website at www.aligos.com. A replay of the webcast will be available following the presentation for at least 30 days.
About Aligos
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus infection.
For more information, please visit www.aligos.com or follow us on LinkedIn or X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ plans to advance its pipeline and develop best-in-class therapies for the treatment of liver and viral diseases. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, and other matters that could affect the sufficiency of Aligos’ capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2026 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
Investor Contact
Aligos Therapeutics, Inc.
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
+1 (650) 910-0427
jtarazi@aligos.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.